Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.9 Billion JPY | 8971.88% |
| 2022 | 32 Million JPY | 196.97% |
| 2021 | -33 Million JPY | 89.42% |
| 2020 | -312 Million JPY | 0.0% |
| 2019 | - JPY | 0.0% |
| 2018 | - JPY | 0.0% |
| 2017 | - JPY | 0.0% |
| 2016 | - JPY | 0.0% |
| 2015 | - JPY | -100.0% |
| 2014 | 723 Thousand JPY | -5.74% |
| 2013 | 767 Thousand JPY | 34.09% |
| 2012 | 572 Thousand JPY | 5620.0% |
| 2011 | 10 Thousand JPY | -99.98% |
| 2010 | 62.98 Million JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| 2006 | - JPY | 0.0% |
| 2005 | - JPY | 0.0% |
| 2004 | - JPY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q3 | 1.63 Billion JPY | -29.52% |
| 2024 Q2 | 2.31 Billion JPY | 10.93% |
| 2024 Q1 | 2.08 Billion JPY | -28.14% |
| 2023 Q3 | 3.99 Billion JPY | 0.0% |
| 2023 Q4 | 2.9 Billion JPY | -27.35% |
| 2023 FY | 2.9 Billion JPY | 8971.88% |
| 2023 Q2 | - JPY | 0.0% |
| 2023 Q1 | - JPY | -100.0% |
| 2022 FY | 32 Million JPY | 196.97% |
| 2022 Q4 | 32 Million JPY | 0.0% |
| 2022 Q1 | - JPY | 100.0% |
| 2022 Q2 | - JPY | 0.0% |
| 2022 Q3 | - JPY | 0.0% |
| 2021 FY | -33 Million JPY | 89.42% |
| 2021 Q1 | 206 Million JPY | -50.95% |
| 2021 Q2 | - JPY | -100.0% |
| 2021 Q3 | - JPY | 0.0% |
| 2021 Q4 | -33 Million JPY | 0.0% |
| 2020 Q2 | 103 Million JPY | -82.15% |
| 2020 Q1 | 577 Million JPY | -67.31% |
| 2020 Q4 | 420 Million JPY | 5.0% |
| 2020 FY | -312 Million JPY | 0.0% |
| 2020 Q3 | 400 Million JPY | 288.35% |
| 2019 Q3 | 1.29 Billion JPY | -39.57% |
| 2019 FY | - JPY | 0.0% |
| 2019 Q2 | 2.13 Billion JPY | -6.23% |
| 2019 Q1 | 2.28 Billion JPY | 0.0% |
| 2019 Q4 | 1.76 Billion JPY | 36.61% |
| 2018 Q1 | 1.05 Billion JPY | 0.0% |
| 2018 Q3 | - JPY | 0.0% |
| 2018 Q2 | - JPY | -100.0% |
| 2018 FY | - JPY | 0.0% |
| 2017 Q1 | - JPY | 0.0% |
| 2017 FY | - JPY | 0.0% |
| 2017 Q4 | - JPY | 0.0% |
| 2017 Q3 | - JPY | 0.0% |
| 2017 Q2 | - JPY | 0.0% |
| 2016 FY | - JPY | 0.0% |
| 2016 Q4 | - JPY | 0.0% |
| 2016 Q1 | - JPY | -100.0% |
| 2016 Q3 | - JPY | 0.0% |
| 2016 Q2 | - JPY | 0.0% |
| 2015 Q2 | 903 Million JPY | 55.76% |
| 2015 FY | - JPY | -100.0% |
| 2015 Q3 | 871 Million JPY | -3.54% |
| 2015 Q4 | 427 Million JPY | -50.98% |
| 2015 Q1 | 579.72 Million JPY | 115844.6% |
| 2014 Q4 | 500 Thousand JPY | 0.0% |
| 2014 Q3 | 500 Thousand JPY | 0.0% |
| 2014 Q2 | 500 Thousand JPY | -34.81% |
| 2014 Q1 | 767 Thousand JPY | 53.4% |
| 2014 FY | 723 Thousand JPY | -5.74% |
| 2013 FY | 767 Thousand JPY | 34.09% |
| 2013 Q1 | 572 Thousand JPY | 166.05% |
| 2013 Q2 | 94.76 Million JPY | 16466.96% |
| 2013 Q4 | 500 Thousand JPY | 0.0% |
| 2013 Q3 | - JPY | -100.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q1 | 10 Thousand JPY | -98.93% |
| 2012 FY | 572 Thousand JPY | 5620.0% |
| 2012 Q4 | 215 Thousand JPY | 0.0% |
| 2012 Q2 | - JPY | -100.0% |
| 2011 FY | 10 Thousand JPY | -99.98% |
| 2011 Q4 | 933 Thousand JPY | 0.0% |
| 2011 Q1 | 62.98 Million JPY | 0.0% |
| 2011 Q3 | - JPY | -100.0% |
| 2011 Q2 | 16 Million JPY | -74.59% |
| 2010 FY | 62.98 Million JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| 2006 FY | - JPY | 0.0% |
| 2005 FY | - JPY | 0.0% |
| 2004 FY | - JPY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 683.01 Million JPY | -325.03% |
| PRISM BioLab Co.,LTD | 17.92 Million JPY | -16091.645% |
| GNI Group Ltd. | 2.33 Billion JPY | -24.559% |
| Linical Co., Ltd. | - JPY | -Infinity% |
| Trans Genic Inc. | 2.22 Billion JPY | -30.314% |
| MEDINET Co., Ltd. | 67.48 Million JPY | -4201.952% |
| Soiken Holdings Inc. | 1.12 Billion JPY | -158.995% |
| Cytori Cell Research Institute, Inc. | 103.53 Million JPY | -2703.91% |
| AnGes, Inc. | 1.61 Billion JPY | -79.662% |
| OncoTherapy Science, Inc. | 73.99 Million JPY | -3823.026% |
| Immuno-Biological Laboratories Co., Ltd. | 321.91 Million JPY | -801.796% |
| NanoCarrier Co., Ltd. | 184 Thousand JPY | -1577617.391% |
| Carna Biosciences, Inc. | 140.14 Million JPY | -1971.5% |
| CanBas Co., Ltd. | 728 Thousand JPY | -398663.736% |
| D. Western Therapeutics Institute, Inc. | 87.86 Million JPY | -3204.007% |
| RaQualia Pharma Inc. | 147.93 Million JPY | -1862.295% |
| Chiome Bioscience Inc. | 64.1 Million JPY | -4428.367% |
| Kidswell Bio Corporation | 875.65 Million JPY | -231.524% |
| PeptiDream Inc. | 2.4 Billion JPY | -20.749% |
| Oncolys BioPharma Inc. | 5.34 Million JPY | -54242.943% |
| Ribomic Inc. | 2.27 Million JPY | -127560.51% |
| SanBio Company Limited | - JPY | -Infinity% |
| Healios K.K. | - JPY | -Infinity% |
| BrightPath Biotherapeutics Co., Ltd. | 1.00 JPY | -290299999900.0% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 36 Million JPY | -7963.889% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | 29 Million JPY | -9910.345% |
| CellSource Co., Ltd. | 305.92 Million JPY | -848.925% |
| FunPep Company Limited | 25.54 Million JPY | -11266.039% |
| Kringle Pharma, Inc. | 364.05 Million JPY | -697.405% |
| Stella Pharma Corporation | 1.11 Billion JPY | -160.066% |
| TMS Co., Ltd. | 50.02 Million JPY | -5703.098% |
| Noile-Immune Biotech Inc. | 20.9 Million JPY | -13789.288% |
| Cuorips Inc. | 1.04 Million JPY | -278231.735% |
| K Pharma,Inc. | 10.79 Million JPY | -26794.571% |
| Takara Bio Inc. | 11.85 Billion JPY | 75.502% |
| ReproCELL Incorporated | 248.14 Million JPY | -1069.904% |
| PhoenixBio Co., Ltd. | 450.58 Million JPY | -544.271% |
| StemCell Institute Inc. | 42.26 Million JPY | -6769.055% |
| Japan Tissue Engineering Co., Ltd. | 228.56 Million JPY | -1170.098% |
| CellSeed Inc. | 46.19 Million JPY | -6184.774% |